| Adamas Pharmaceuticals focuses on time-dependent medicines to enhance the daily living experience of those affected by entral nervous system disorders. Co.'s portfolio includes: GOCOVRI (amantadine) extended-release capsules is for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; and Potential Additional Indications for GOCOVRI (amantadine) Extended Release Capsule (ADS-5102 ), which is in development for the treatment of walking impairment in patients with multiple sclerosis. ADS-5102 is also in research and potential development for additional indications. We show 27 historical shares outstanding datapoints in our coverage of ADMS's shares outstanding history.|
Understanding the changing numbers of ADMS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADMS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADMS by allowing them to research ADMS shares outstanding history
as well as any other stock in our coverage universe.